Reintroduction of anti-TNFα therapy after (or even during) anti-TNFα-associated tuberculosis in immune-mediated diseases

Journal of Crohn's and Colitis

Volumn 10, Issue 1, 2016, Pages 120-121

  Abreu, C ^a,b   Sarmento, A ^a,b   Magro, F ^a,c,d  

^a Universidade do Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

COHORT ANALYSIS; CROHN DISEASE; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; IMMUNE MEDIATED INJURY; LETTER; MENINGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ADULT; AGED; ANTAGONISTS AND INHIBITORS; COMORBIDITY; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84963724929     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv172     Document Type: Letter

References (5)

1. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015;14:503-9
2. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-68
3. Masia M, Martinez M, Garcia-Sepulcre MF, Saez J, Gutierrez F. Recurrence of active tuberculosis following resumption of anti-TNF-alpha therapy in a patient with Crohn's disease. Int J Tuberc Lung Dis 2014;18:249-50
4. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of lifethreatening tuberculosis. Clin Infect Dis 2009;48:1429-32
5. Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohn Colitis 2013;7:e486-92